HKSE - Delayed Quote • HKD
TOT BIOPHARM International Company Limited (1875.HK)
At close: April 26 at 2:01 PM GMT+8
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 1 | 1 |
| Avg. Estimate | 806.97M | -- | 806.97M | 833.57M |
| Low Estimate | 806.97M | -- | 806.97M | 833.57M |
| High Estimate | 806.97M | -- | 806.97M | 833.57M |
| Year Ago Sales | -- | -- | -- | 806.97M |
| Sales Growth (year/est) | -- | -- | -- | 3.30% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0.02 | 0.06 |
| 30 Days Ago | 0 | 0 | 0.02 | 0.06 |
| 60 Days Ago | 0 | 0 | 0.02 | 0.06 |
| 90 Days Ago | 0 | 0 | 0.02 | 0.06 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | 1875.HK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 5.40% |
| Next Qtr. | -- | -- | -- | 10.90% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker
Related Tickers
6662.TWO BioLASCO Taiwan Co., Ltd.
35.65
-0.42%
6733.TWO BioGend Therapeutics Co., Ltd.
36.60
+1.10%
6875.TWO Pharmosa Biopharm Inc.
64.50
-1.23%
6535.TWO Lumosa Therapeutics Co., Ltd.
172.00
+0.29%
6712.TWO Ever Supreme Bio Technology Co., Ltd
207.00
-2.13%
6949.TW PELL Bio-Med Technology Co. Ltd.
173.00
+9.84%
4726.TWO Mycenax Biotech Inc.
43.85
-4.67%